Xilio Therapeutics, Inc. Common Stock (XLO)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 76
- Market Cap
- $60M
About Xilio Therapeutics, Inc. Common Stock
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
SentiSense also tracks daily options readings for Xilio Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Xilio Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.